ClinicalTrials.gg
TerminatedNCT07116499Updated Nov 5, 2026Results posted

A Study of K-645 in the Treatment of Multiple Migraine Attacks

A Phase 2 interventional study of K-645 100 mg and K-645 10 mg in Migraine, sponsored by TriGemX Bio, Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by TriGemX Bio, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Study stopped for futility based on an interim analysis of efficacy.
Updated Nov 5, 2026Results postedStudy documents posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
240th of 610
134 · median 78
Started
2025
with 31 others
Phase 2
90 of 697
7 open now
Registered
653rd of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 240th largest by enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2025, is one of 90 in phase 2, and was the 653rd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

INCLUSION CRITERIA:

  1. Be a male or female, age 18 to 65 years, inclusive, at the time of signing .
  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Headache Society (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated (refer to International Classification of Headache Disorders [ICHD] III Attachment for IHS migraine definitions) as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.
  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to Screening (Visit 1).
  4. Meet the following requirements:

    1. Is a male who agrees to all of the following:

      • If partner is a non-pregnant female of : To use an appropriate method of , including a condom with spermicidal cream or jelly, from the first dose of study drug until ≥72 hours after the last dose of study drug (i.e. Period 3). A male participant who has had a vasectomy procedure must use a condom but is not required to use spermicidal cream or jelly.
      • If partner is pregnant: To use a condom from the first dose of study drug until ≥72 hours after the last dose of study drug.

      Note: Contraception/condom requirements are waived if partner is NOT of childbearing potential (i.e. is male or is a female who is or surgically sterile [post-hysterectomy or bilateral salpingectomy]).

      • To not donate sperm from the first dose of study drug until ≥72 hours after the last dose of study drug.

      OR

    2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

      • Postmenopausal defined as one of the following: a minimum of 12 months of spontaneous amenorrhea OR a minimum of 6 months of spontaneous amenorrhea with a Screening serum follicle-stimulating hormone (FSH) level >40 mIU/mL OR at least 6 weeks post-bilateral oophorectomy (with or without hysterectomy).
      • Post hysterectomy or bilateral salpingectomy, based on the participant's recall of their medical history.
      • If pre-menopausal, they must agree to not donate eggs from the first dose of study drug until 30 days after the last dose study drug.

    OR c. Is a female of and:

    • agrees to not donate eggs from the first dose of study drug until 30 days after the last dose study drug.

    AND

    • agrees to remain abstinent from heterosexual activity*,** or
    • agrees to use (or have their partner use) a birth control method that is highly effective**. Acceptable methods of birth control are:

      • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
      • Progestogen-only contraception (e.g. oral, injectable, implant) associated with inhibition of ovulation
      • Intrauterine device (IUD)
      • Intrauterine hormone-releasing system (IUS)
      • Bilateral tubal occlusion
      • Vasectomized partner * Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

        • Note: Participants must agree that they will not attempt to become pregnant during the cycles of study drug administration or the menstrual cycle following the last dose of study medication.
  5. Voluntarily agrees to participate in the study by giving written informed consent.
  6. Is able to read, understand, and complete the study questionnaires and diary.
  7. Be willing and able to comply with the study schedule of visits and all trial procedures and restrictions.
  8. Be willing to use their own personal, qualified smartphone to download study-specific eDiary applications for use during the study.

KEY EXCLUSION CRITERIA:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Female participants of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history-related exclusion criteria

  2. Has difficulty distinguishing his/her migraine attacks from tension-type headaches.
  3. Has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.
  4. Has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to Screening (Visit 1).
  5. Has brainstem (also known as [a.k.a.] basilar-type) or hemiplegic migraine headache, or retinal migraine.
  6. Was >50 years old at age of first migraine onset.
  7. Is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to Screening (Visit 1) or anticipates any change during the study.
  8. Stopped preventive migraine medication(s) within 30 days prior to Screening for small molecules or 90 days for antibodies.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    K-645 100 mg - Placebo - K-645 10 mg

    In treatment sequence 1, participants were randomized to receive single oral doses of K-645 100 mg, matching placebo, and then K-645 10 mg during Periods1, 2, and 3, respectively.

    Drug: K-645 100 mg · Drug: K-645 10 mg · Drug: Placebo

  • Experimental
    Placebo - K-645 100 mg - K-645 10 mg

    In treatment sequence 2, participants were randomized to receive single oral doses of matching placebo, K-645 100 mg, and then K-645 10 mg during Periods 1, 2, and 3, respectively.

    Drug: K-645 100 mg · Drug: K-645 10 mg · Drug: Placebo

Interventions

  • DrugK-645 100 mg

    Single oral dose of K-645 100 mg

  • DrugK-645 10 mg

    Single oral dose of K-645 10 mg

  • DrugPlacebo

    Single oral dose of matching placebo

06

What researchers measure

Primary outcomes

  1. Pain Freedom

    Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)

    Assessed using the number of evaluable participants that reported the absence of their MBS. The MBS was measured using a binary scale (0 = absent, 1 = present)

    Time frame: 2 hours post-dose

  2. Pain Relief

    Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

    Time frame: 2 hours post-dose

  3. Percentage of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)

    Time frame: Up to 7 days after the last dose of study medication

  4. Percentage of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)

    Serious adverse events were assessed in the Safety Analysis Set.

    Time frame: Up to 7 days after the last dose of study medication

07

Results

Posted Nov 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneK-645 100 mg - Placebo - K-645 10 mgPlacebo - K-645 100 mg - K-645 10 mg
Started6767
Completed1823
Not completed4944

Outcome measures

PrimaryPain Freedom

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Pain Freedom
ParticipantsPlaceboK-645 100 mgK-645 10 mg
Pain Freedom1253
Statistical analysis
  • Placebo vs K-645 100 mg · Delta method · p = 0.0459 (One-sided p-value, calculated as half of the 2-sided p-value) · Risk difference (rd): -7.18 · 90% CI -13.97 to -0.39The 90% CI comparing K-645 100mg with Placebo was derived from logistic regression.
SecondaryFreedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)

Assessed using the number of evaluable participants that reported the absence of their MBS. The MBS was measured using a binary scale (0 = absent, 1 = present)

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)
ParticipantsPlaceboK-645 100 mgK-645 10 mg
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)171710
Statistical analysis
  • Placebo vs K-645 100 mg · Delta method · p = 0.4011 (One-sided p-value, calculated as half of the 2-sided p-value) · Risk difference (rd): -1.47 · 90% CI -11.17 to 8.23The 90% CI comparing K-645 100mg with Placebo was derived from logistic regression.
SecondaryPain Relief

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Pain Relief
ParticipantsPlaceboK-645 100 mgK-645 10 mg
Pain Relief393015
Statistical analysis
  • Placebo vs K-645 100 mg · Delta method · p = 0.0622 (One-sided p-value, calculated as half of the 2-sided p-value) · Risk difference (rd): -10.31 · 90% CI -21.26 to 0.63The 90% CI comparing K-645 100mg with Placebo was derived from logistic regression.
SecondaryPercentage of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Time frame:
Up to 7 days after the last dose of study medication
Reported as:
Count of participants · Participants
Percentage of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
ParticipantsPlaceboK-645 100 mgK-645 10 mg
Percentage of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)342
SecondaryPercentage of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)

Serious adverse events were assessed in the Safety Analysis Set.

Time frame:
Up to 7 days after the last dose of study medication
Reported as:
Count of participants · Participants
Percentage of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsPlaceboK645 100 mgK645 10 mg
Percentage of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)000

Adverse events

Collected over Up to 7 days after administration of study medication. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/104 (0%)0/104 (0%)3/104 (2.9%)
K-645 100 mg0/108 (0%)0/108 (0%)4/108 (3.7%)
K-645 10 mg0/41 (0%)0/41 (0%)2/41 (4.9%)
Most frequent other events
Most frequent other events
EventPlaceboK-645 100 mgK-645 10 mg
Temporomandibular pain and dysfunction syndromeMusculoskeletal and connective tissue disorders0/1041/1081/41
Thermal burnInjury, poisoning and procedural complications0/1040/1081/41
Back painMusculoskeletal and connective tissue disorders1/1040/1080/41
Vision blurredEye disorders1/1040/1080/41
Tooth abscessInfections and infestations1/1040/1080/41
Neck painMusculoskeletal and connective tissue disorders0/1041/1080/41
NauseaGastrointestinal disorders0/1041/1080/41
SomnolenceNervous system disorders0/1041/1080/41

Baseline characteristics

The baseline analysis population included all participants who were in the modified Intent-to-Treat (mITT) analysis set for the primary endpoint for at least one study medication. For each study medication, the mITT set for the primary endpoint comprised all randomized participants who took that study medication to treat a qualifying migraine of moderate/severe baseline pain intensity (Grade 2 or 3, on a 4-point numeric rating) and provided a pain rating at baseline and at 2 hours post-dose.

Age, Continuous
Age, Continuous(years)K-645 100 mg - Placebo - K-645 10 mgPlacebo - K-645 100 mg - K-645 10 mgTotal
Mean44.1 ± 11.3745.2 ± 11.3344.7 ± 11.31
Age, Customized
Age, Customized(Participants)K-645 100 mg - Placebo - K-645 10 mgPlacebo - K-645 100 mg - K-645 10 mgTotal
<65 years5862120
≥65 years123
Sex: Female, Male
Sex: Female, Male(Participants)K-645 100 mg - Placebo - K-645 10 mgPlacebo - K-645 100 mg - K-645 10 mgTotal
Female5355108
Male6915
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)K-645 100 mg - Placebo - K-645 10 mgPlacebo - K-645 100 mg - K-645 10 mgTotal
Hispanic or Latino7916
Not Hispanic or Latino5153104
Unknown or Not Reported123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)K-645 100 mg - Placebo - K-645 10 mgPlacebo - K-645 100 mg - K-645 10 mgTotal
American Indian or Alaskan Native000
Asian112
Black or African American71421
Native Hawaiian or Other Pacific Islander000
White494695
Other011
Multiple213
Not Reported/Unknown011
08

Study locations

18 sites
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • DelRicht Research - Atlanta
    Atlanta, Georgia 30329, United States
  • Clinical Research Atlanta - Stockbridge
    Stockbridge, Georgia 30281, United States
  • Chicago Headache Center and Research Institute
    Chicago, Illinois 60657, United States
  • Collective Medical Research
    Overland Park, Kansas 66202, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • DelRicht Research - Prairieville
    Prairieville, Louisiana 70817, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • Peters Medical Research
    High Point, North Carolina 27260, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • DM Clinical Research - Bellaire
    Houston, Texas 77081, United States
  • APD Clinical Research
    Splendora, Texas 77372, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Nov 2025, 3 months.

Results were first posted in Nov 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 11, 2025
StartActual
Aug 13, 2025
Primary completionActual
Nov 18, 2025
CompletionActual
Nov 18, 2025
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Start date
Aug 12, 2025→Aug 13, 2025
Nov 5, 2026
Primary completion
Nov 7, 2025→Nov 18, 2025
Nov 5, 2026
Study completion
Nov 7, 2025→Nov 18, 2025
Nov 5, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedPatientParticipant has greater than a one-year history of migraine with or without aura as defined by International Headache Society (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated (refer to International Classification of Headache Disorders [ICHD] III Attachment for IHS migraine definitions) as documented in the patientparticipant's medical records from his/her treating physician and confirmed by the investigator.
  • EditedPatientParticipant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to Screening (Visit 1).
Nov 5, 2026
Interventions
Added Drug: K-645 100 mg·Drug: K-645 10 mg; removed Drug: K-645 dose level 1·Drug: K-645 dose level 2. Arms added: K-645 100 mg - Placebo - K-645 10 mg·Placebo - K-645 100 mg - K-645 10 mg; arms removed: Treatment Sequence 1·Treatment Sequence 2
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of participants with pain freedomPain FreedomTime frame: 2 hours post-dose
Nov 5, 2026
Documents
Secondary outcomes
2 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedPercentage of participants who experiencedParticipants Who Experienced 1 or more treatmentMore Treatment-emergent adverse eventsAdverse Events (AEs)Time frame: up to 7 days after the last dose of study medication → Up to 7 days after the last dose of study medication
  • EditedPercentage of participants who experiencedParticipants Who Experienced 1 or more treatmentMore Treatment-emergent serious adverse eventsSerious Adverse Events (SAEs)Time frame: up to 7 days after the last dose of study medication → Up to 7 days after the last dose of study medication
  • AddedFreedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)Time frame: 2 hours post-dose
  • AddedPain ReliefTime frame: 2 hours post-dose
  • RemovedPercentage of participants with freedom from the most bothersome symptomTime frame: 2 hours post-dose
  • RemovedPercentage of participants who report pain reliefTime frame: 2 hours post-dose
Nov 5, 2026
Sponsor
Kallyope Inc.→TriGemX Bio, Inc.
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Start date Aug 12, 2025→Aug 13, 2025
    Primary completion Nov 7, 2025→Nov 18, 2025
    Study completion Nov 7, 2025→Nov 18, 2025
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedPatientParticipant has greater than a one-year history of migraine with or without aura as defined by International Headache Society (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated (refer to International Classification of Headache Disorders [ICHD] III Attachment for IHS migraine definitions) as documented in the patientparticipant's medical records from his/her treating physician and confirmed by the investigator.
    • EditedPatientParticipant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to Screening (Visit 1).
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of participants with pain freedomPain FreedomTime frame: 2 hours post-dose
    Secondary outcomes 2 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedPercentage of participants who experiencedParticipants Who Experienced 1 or more treatmentMore Treatment-emergent adverse eventsAdverse Events (AEs)Time frame: up to 7 days after the last dose of study medication → Up to 7 days after the last dose of study medication
    • EditedPercentage of participants who experiencedParticipants Who Experienced 1 or more treatmentMore Treatment-emergent serious adverse eventsSerious Adverse Events (SAEs)Time frame: up to 7 days after the last dose of study medication → Up to 7 days after the last dose of study medication
    • AddedFreedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)Time frame: 2 hours post-dose
    • AddedPain ReliefTime frame: 2 hours post-dose
    • RemovedPercentage of participants with freedom from the most bothersome symptomTime frame: 2 hours post-dose
    • RemovedPercentage of participants who report pain reliefTime frame: 2 hours post-dose
    Interventions Added Drug: K-645 100 mg·Drug: K-645 10 mg; removed Drug: K-645 dose level 1·Drug: K-645 dose level 2. Arms added: K-645 100 mg - Placebo - K-645 10 mg·Placebo - K-645 100 mg - K-645 10 mg; arms removed: Treatment Sequence 1·Treatment Sequence 2
    Sponsor Kallyope Inc.→TriGemX Bio, Inc.
    + 4 other changes: index terms, identifiers, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07116499
Lead sponsor
TriGemX Bio, Inc.
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Aug 13, 2025
Primary completion
Nov 18, 2025
Completion
Nov 18, 2025
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion